2025-524205-32-00
Recruiting
Phase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants with Atopic Dermatitis
Regeneron Pharmaceuticals Inc.0 sites64 target enrollmentStarted: May 4, 2026Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Regeneron Pharmaceuticals Inc.
- Enrollment
- 64
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
Similar Trials
Not yet recruiting
Phase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisHealthy VolunteerAtopic DermatitisNCT07527923Regeneron Pharmaceuticals136
Not yet recruiting
Phase 1
A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy AdultsHealthy VolunteerNCT07526116Regeneron Pharmaceuticals64
Recruiting
Phase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisNCT07410117Regeneron Pharmaceuticals860
Completed
Phase 1
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants.2022-500398-15-00Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.64
Not yet recruiting
Phase 2
The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort StudyNCT07464366Ji Dongmei68